NCT03688633: NEUPERSART

Candesartan in Peripheral Neuropathy

Terminated Phase 2 Last updated 15 November 2021

What this trial tests

Phase 2 trial testing Candesartan in Peripheral Neuropathy in 9 participants. Terminated before completion.

Timeline

1 May 2019

Primary endpoint
27 May 2021

27 May 2021

Quick facts

Lead sponsor	University Hospital, Limoges
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	9
Start date	1 May 2019
Primary completion	27 May 2021
Estimated completion	27 May 2021
Sites	1 location across France

Drugs / interventions tested

• Candesartan — full drug profile →
• Usual care

Conditions studied

• Peripheral Neuropathy — all drugs for Peripheral Neuropathy →

Sponsor

University Hospital, Limoges

Who can join

Adults 18 to 80, any sex, with Peripheral Neuropathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background:

Chemotherapy induced peripheral neuropathy (CIPN) is often painful, and is caused by neurotoxic chemotherapy including vincristine. It is a cause of significant impairment in quality of life in patients surviving to a solid cancer or malignant lymphoma. The only recognized prevention is based on pre-existing neuropathy and early detection of neuropathic signs and symptoms in individuals subjected to neurotoxic chemotherapy, justifying sometimes a change in the therapeutic strategy when other molecules are available. It seems obvious that to identify early markers of CIPN and to develop preventive therapeutic strategies, are priorities for improving patients' quality of life and enable them to follow optimal treatment.

Purpose:

To describe in patients treated for non-Hodgkin's type B malignant lymphoma with multidrug therapy containing vincristine, the impact of candesartan on the occurrence of neuropathy measured by the variation of TNSc (Total Neuropathy Score clinical version, evaluating clinical signs of neuropathy)

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Emerging Pharmacological and Non-Pharmacological Therapeutics for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy.
   Li Y, Lustberg MB, Hu S. · · 2021 · cited 36× · PMID 33673136 · DOI 10.3390/cancers13040766